Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The gut microbiome is emerging as a novel therapeutic target for the treatment of severe mental illness. However, the lack of knowledge on how gut microbiome features can manifest into specific mental health phenotypes is currently limiting the development of therapeutics. In this chapter, I present the evidence suggesting the existence of a gut microbiome-endocannabinoid axis of relevance to anhedonia/amotivation, debilitating symptoms and unmet therapeutic needs in psychotic illness.

Original publication





Book title

Prevention in Mental Health: From Risk Management to Early Intervention

Publication Date



311 - 323